ALK and anaplastic large cell lymphoma: Out of 8 patients treated who had active disease at time of infusion, 2 patients went into CR with 1 patient with ALK+ ALCL maintaining CR for 9 months before relapse, and the other patient with HL continuing to be in CR for greater than 2.5 years at time of publication [32].